Major Depression Clinical Trial
Official title:
A Spirituality Teaching Program for Depression in Adults: A Randomized Controlled Trial
Major depression is a widely spread health problem in Canada. Recent research suggests a
potential role for religion/spirituality in the prevention of and recovery from depression
in adults. The purpose this study was to assess the efficacy of a home-based Spirituality
Teaching Program for adults in the treatment of major depression. The objectives of the
study were to determine:
1. whether the Spirituality Teaching Program is efficacious in improving depression
severity, response rate, and remission rate in adults,
2. whether efficacy is maintained long term (over a 16 week period).
Status | Completed |
Enrollment | 84 |
Est. completion date | December 2008 |
Est. primary completion date | December 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Satisfy the DSM-IV criteria for unipolar major depression with a depression score of 18-22 on the Hamilton Depression Scale (mild to moderate severity), - Are at least 18 years of age, - Have the competence to understand the study requirements and the ability to comply with the study intervention, - Have provided written informed consent. Exclusion Criteria: - History of treatment resistance to two or more antidepressants when treated for an adequate period with a therapeutic dose - History of bipolar d/o, psychotic d/o, any psychotic episodes, personality d/o (except obsessive compulsive d/o) - History of multiple suicide attempts - Acute psychiatric condition other than unipolar depression - Regular use of medications (other than antidepressant, if applicable) that have mood altering effects, such as narcotics, anticonvulsants, illicit drugs or sleeping pills - Uncontrolled medical conditions in the last 3 months - DSM-IV diagnosis of substance abuse (except nicotine and caffeine) within the past 12-months - High suicide risk |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Canadian Institute of Natural and Integrative Medicine | Calgary | Alberta |
Lead Sponsor | Collaborator |
---|---|
Canadian Institute of Natural and Integrative Medicine | A.T. Still University, Arizona School of Health Sciences, Alberta Health Services, Southwest Behavioral Health Sciences, The Center for Mind-Body Medicine, University of Calgary, Dept. of Psychiatry & Dept. of Community Health Sciences |
Canada,
Moritz S, Kelly MT, Xu TJ, Toews J, Rickhi B. A spirituality teaching program for depression: qualitative findings on cognitive and emotional change. Complement Ther Med. 2011 Aug;19(4):201-7. doi: 10.1016/j.ctim.2011.05.006. Epub 2011 Jun 29. — View Citation
Rickhi B, Moritz S, Reesal R, Xu TJ, Paccagnan P, Urbanska B, Liu MF, Ewing H, Toews J, Gordon J, Quan H. A spirituality teaching program for depression: a randomized controlled trial. Int J Psychiatry Med. 2011;42(3):315-29. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hamilton Depression Rating Scale - Depression Severity | Depression severity was assessed at the four time points (baseline, 8 weeks, 16 weeks and 24 weeks) using the Hamilton Depression Rating Scale (HAM-D). The HAM-D is a standardized outcome measure of depression severity in adults. Total scores includes the sum of 17-items, with eight items scored on a range of 0 (absent) to 2 (marked or definite) and nine scored on a range of 0 (absent) to 4 (very severe). The level of depression was based on the following scoring ranges: 7 or under not depressed, 8-13 some depressive symptoms but no depressive disorder, 12-15 mild depression, 16-19 moderate depression, 20-24 moderately severe depression, and 25+ severe depression. The HAM-D was administered through a face to face interview, which was conducted by a trained nurse who was blinded to participants' allocation. |
baseline, 8 weeks, 16 weeks, and 24 weeks | No |
Secondary | Response Rate | Response rate was assessed at the four time points (baseline, 8 weeks, 16 weeks and 24 weeks) using the Hamilton Depression Rating Scale (HAM-D). A response was determined as a reduction in the HAM-D score by at least 50% from the baseline score. The data are presented as the percentage of participants with response at each time point as compared to baseline. | baseline, 8 weeks, 16 weeks, and 24 weeks | No |
Secondary | Remission | Remission of depression was assessed at the four time points (baseline, 8 weeks, 16 weeks and 24 weeks) using the Hamilton Depression Rating Scale (HAM-D). Remission was based on a HAM-D score of less than 7. Remission is indicated as a percentage of participants at each time point whose scores were below 7. | baseline, 8 weeks, 16 weeks, and 24 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03062150 -
Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression
|
N/A | |
Completed |
NCT04352101 -
Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits
|
Phase 4 | |
Completed |
NCT02855918 -
Blood Biomarkers in Suicidal Behaviour
|
N/A | |
Recruiting |
NCT03039387 -
Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients
|
N/A | |
Recruiting |
NCT02213016 -
Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients
|
Phase 4 | |
Completed |
NCT01636791 -
CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care
|
Phase 3 | |
Completed |
NCT01683539 -
Understanding How Cognitive Remediation Works
|
N/A | |
Recruiting |
NCT02237937 -
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
|
Phase 4 | |
Completed |
NCT01201148 -
Open Pilot Trial of TES for Depression
|
Phase 2 | |
Completed |
NCT00953108 -
Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients
|
Phase 3 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Terminated |
NCT00695552 -
The Effect of Exercise on Depressive Symptoms in Unmedicated Patients
|
N/A | |
Completed |
NCT00806143 -
Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression
|
Phase 4 | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00466323 -
The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
|
N/A | |
Completed |
NCT00532480 -
Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine
|
Phase 4 | |
Completed |
NCT00482482 -
Yoga in Unipolar and Bipolar Disorders
|
N/A | |
Completed |
NCT00616759 -
The Effect on Cognition of Terminating ECT Induced Seizures With Propofol
|
N/A | |
Recruiting |
NCT00209807 -
Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
|
Phase 4 | |
Completed |
NCT00149110 -
Chronos: the Use of Chronobiological Treatment in Depression
|
N/A |